VP 16β213 and cyclophosphamide in the tr
β
Hurd, David D. ;Peterson, Bruce A. ;McKenna, Robert W. ;Bloomfield, Clara D.
π
Article
π
1981
π
John Wiley and Sons
π
English
β 281 KB
## Abstract The treatment of refractory acute nonlymphocytic leukemia remains a major clinical problem in leukemia therapy. VP 16β213 is an investigational agent that may have specificity for monocytic blasts, and the combination of VP 16β213 and cyclophosphamide is synergistic in experimental leuk